GDF2
Growth/differentiation factor 2
Protein Summary
Potent circulating inhibitor of angiogenesis. Signals through the type I activin receptor ACVRL1 but not other Alks. Signaling through SMAD1 in endothelial cells requires TGF-beta coreceptor endoglin/ENG. This gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Ligands of this family bind various TGF-beta receptors leading to recruitment and activation of SMAD family transcription factors that regulate gene expression. The encoded preproprotein is proteolytically processed to generate each subunit of the disulfide-linked homodimer. This protein regulates cartilage and bone development, angiogenesis and differentiation of cholinergic central nervous system neurons. Mutations in this gene are associated with hereditary hemorrhagic telangiectasia. [provided by RefSeq, Jul 2016]
- ENST00000581492
- ENSP00000463051
- ENSG00000263761
- BMP9
- BMP9
- HHT5
- BMP-9
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
biological process | 0.99 | ||
protein domain | 0.85 | ||
tissue | 0.58 | ||
biological term | 0.56 | ||
cell type or tissue | 0.55 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 350.16 (req: < 5)
Gene RIFs: 113 (req: <= 3)
Antibodies: 332 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 350.16 (req: >= 5)
Gene RIFs: 113 (req: > 3)
Antibodies: 332 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 36
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0